SING GEORGE L

SING GEORGE L has demonstrated a clear selling bias in their trading activity involving Regeneron Pharmaceuticals (REGN), with $9.9 million in total sales compared to $8.2 million in purchases across 24 transactions. The most recent trades, all sales, occurred in late 2025 and early 2026, including two high-value dispositions on December 30, 2025, worth $4.79 million each. Earlier in 2024, SING executed a series of smaller but consistent sales, including five transactions in February alone, with the largest single sale on February 22, 2024, totaling $970,000. The pattern suggests a gradual reduction in holdings, with no recent purchases recorded. The transactions are concentrated solely in REGN, indicating no diversification across other securities. While some filings show $0 value transactions—likely representing grants, awards, or adjustments—the monetized sales dominate the activity. The largest dispositions cluster at year-end, with December 30, 2025, standing out as the peak selling period. The absence of buys since at least early 2024 reinforces the net divestment trend, though the retained holdings (evidenced by ongoing awards) suggest SING maintains a position in the company. The data reflects a methodical, multi-year sell-down rather than abrupt liquidation.